URGN

Urogen Pharma Stock Analysis

AI Rating

Neutral
  • Quality3/10
  • Growth↓ 1/10
  • Momentum↑ 9/10
Urogen Pharma sales and earnings growth
URGN Growth
Low
  • Revenue Y/Y↑ 8.00%
  • EPS Y/Y↓ -13.99%
  • FCF Y/Y↓ -43.31%
Urogen Pharma gross and profit margin trends
URGN Profitability
Fair
  • Gross margin ↑ 88.00%
  • EPS margin↓ -170.60%
  • ROIC↓ -74.20%
Urogen Pharma net debt vs free cash flow
URGN Risk
Great
  • Debt / Equity↓ -1.1
  • Debt / FCF↓ 0.3
  • Interest coverage↓ -9.4

Urogen Pharma stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗